In vivo distribution of arsenic after i.p. injection of arsonoliposomes in balb-c mice

Antimisiaris, Sophia G.; Klepetsanis, Pavlos; Zachariou, Venetia; Giannopoulou, Efstathia; Ioannou, Panagiotis

doi:10.1016/j.ijpharm.2004.11.002

Cited by 24 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dose effects of diarsenic oxide on tumor growth inhibition are consistent with many previous reports (16,17). Also, with these doses, it has been reported that no acute toxicity or effect on the body or organ weight of the mice was observed (16).…”

Section: Discussionsupporting

confidence: 90%

“…As there is no good animal model for inorganic arsenic-related human cancer, we used 10 μg/gBW arsenic doses, higher than the physiological criteria in dietary intakes of inorganic arsenic compounds (120 μg/day females and 214 μg/day males) (15). The dose effects of diarsenic oxide on tumor growth inhibition are consistent with many previous reports (16,17). Also, with these doses, it has been reported that no acute toxicity or effect on the body or organ weight of the mice was observed (16).…”

Section: Discussionsupporting

confidence: 66%

See 1 more Smart Citation

Comparison of diarsenic oxide and tetraarsenic oxide on anticancer effects: Relation to the apoptosis molecular pathway

Chang

Bae²,

Kwak³

et al. 2007

Int J Oncol

View full text Add to dashboard Cite

Abstract. As 2 O 3 has been reported to induce apoptosis and inhibit the proliferation of various human cancer cells. We evaluated the ability of a novel arsenic compound, As 4 O 6 , along with As 2 O 3 in vitro and in vivo. To examine the levels of apoptosis of HPV 16-positive SiHa cervical cancer cell, flow cytometry and Western blotting were employed at various time intervals after two arsenic compound treatments. Ingenuity Pathway Analysis (IPA) was applied to investigate the differential cell death pathway of As 4 O 6 and As 2 O 3 . The results showed that As 4 O 6 was more effective in suppressing SiHa cell growth in vitro and in vivo compared to As 2 O 3 . In addition, the cell cycle was arrested at the sub-G 1 phase by As 4 O 6 . Western blot analysis showed that the proliferating cell nuclear antigen (PCNA) and Bcl-X L with sequence homology to Bcl-2 were significantly suppressed by As 4 O 6 . However, the apoptosis-related proteins such as p21 and Bax were overexpressed by As 4 O 6 . IPA suggested that there is a significant difference between As 2 O 3 -and As 4 O 6 -induced cell death pathways. Taken together, As 4 O 6 has a specific cell death pathway and possesses more potent anti-tumor effects on human cervical cancer cells in vitro and in vivo.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 66%

Comparison of diarsenic oxide and tetraarsenic oxide on anticancer effects: Relation to the apoptosis molecular pathway

Chang

Bae²,

Kwak³

et al. 2007

Int J Oncol

View full text Add to dashboard Cite

show abstract

“…As summarized before [2], promising results were obtained with some of the arsonoliposome types prepared, for which a differential toxicity towards cancer and normal cells was demonstrated [3,4] as well as in vitro antiparasitic activity [5]. However, it has been found that the membrane integrity of arsonoliposomes [6,7] and their in vivo distribution (of arsenic) [8,9] are influenced by the lipid composition of the arsonoliposome membrane, and this has been pinpointed as the reason -or at least one of the reasons -for the different antiparasitic activities demonstrated (in vitro and in vivo), by different arsonoliposome types (with different lipid compositions) [10].…”

Section: Introductionmentioning

confidence: 99%

Does the lipid membrane composition of arsonoliposomes affect their anticancer activity? A cell culture study

Zagana

Haikou

Giannopoulou

et al. 2009

Molecular Nutrition Food Res

Self Cite

View full text Add to dashboard Cite

Sonicated arsonoliposomes were prepared using arsonolipid with palmitic acid acyl chain (C16), mixed with phosphatidylcholine (PC)-based or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC)-based, and cholesterol (Chol) with C16/DSPC/Chol 8:12:10 molar ratio. PEG-lipid (1,2-distearoyl-sn-glycero-3-phosphoethanolamine conjugated to polyethylenoglycol 2000) containing vesicles (PEGylated-arsonoliposomes; PC-based and DSPC-based) were also prepared. The cytotoxicity of these arsonoliposomes towards different cancer cells (human promyelocytic leukaemia NB4, Prostatic cancer PC3, human breast adenocarcinoma MDA-MB-468, human T-lymphocyte (MT-4) and also towards human umbilical vein endothelial cells (HUVECs) was evaluated by calculating the arsonoliposome-induced growth inhibition of the cells by the MTT assay. IC-50 values were interpolated from cell number/arsonoliposome concentration curves. The results reveal that all types of arsonoliposomes evaluated significantly inhibit the growth of most of the cancer cells studied (PC3, NB4, MT4) with the exception of the MDA-MB-468 breast cancer cells which were minimally affected by arsonoliposomes; in some cases even less than HUVEC. Nevertheless, for the same cell type the differences between the different types of arsonoliposomes were significant but not proportional to their stability, indicating that the formation of arsonoliposomes with very stable membranes is not a problem for their anticancer activity. Thereby it is concluded that arsonoliposome composition should be adjusted in accordance to their in vivo kinetics and the desired, for each specific application, biodistribution of As and/or encapsulated drug.

show abstract

“…Pharmacokinetics and biodistribution profiles of arsonolipids revealed that lipid composition had a significant effect on liposome stability and distribution after intraperitoneal administration . For example, arsenic levels in the blood were much higher for pegylated‐arsonoliposomes and mixed arsonoliposomes containing 1,2‐distearoyl‐ sn ‐glycero‐3‐phosphocholine (DSPC; 11.1–21.7% of injected dose at 2 h) than for those containing phosphatidylcholine (PC; 0.269% of injected dose at 3 h).…”

Section: Arsenolipids and Arsenoliposomesmentioning

confidence: 99%

Organic Arsenicals as Functional Motifs in Polymer and Biomaterials Science

Tanaka

Davis

Wilson

2018

Macromol. Rapid Commun.

View full text Add to dashboard Cite

Arsenic (As) exhibits diverse (bio)chemical reactivity and biological activity depending upon its oxidation state. However, this distinctive reactivity has been largely overlooked across many fields owing to concerns regarding the toxicity of arsenic. Recently, a clinical renaissance in the use of arsenicals, including organic arsenicals that are known to be less toxic than inorganic arsenicals, alludes to the possibility of broader acceptance and application in the field of polymer and biomaterials science. Here, current examples of polymeric/macromolecular arsenicals are reported to stimulate interest and highlight their potential as a novel platform for functional, responsive, and bioactive materials.

show abstract

In vivo distribution of arsenic after i.p. injection of arsonoliposomes in balb-c mice

Cited by 24 publications

References 22 publications

Comparison of diarsenic oxide and tetraarsenic oxide on anticancer effects: Relation to the apoptosis molecular pathway

Comparison of diarsenic oxide and tetraarsenic oxide on anticancer effects: Relation to the apoptosis molecular pathway

Does the lipid membrane composition of arsonoliposomes affect their anticancer activity? A cell culture study

Organic Arsenicals as Functional Motifs in Polymer and Biomaterials Science

Contact Info

Product

Resources

About